ACADIA Pharmaceuticals Inc. (ACAD)
| Market Cap | 7.77B |
| Revenue (ttm) | 419.07M |
| Net Income (ttm) | -267.86M |
| Shares Out | 158.13M |
| EPS (ttm) | -1.72 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 24 |
| Last Price | $48.69 |
| Previous Close | $49.74 |
| Change ($) | -1.05 |
| Change (%) | -2.11% |
| Day's Open | 49.77 |
| Day's Range | 48.33 - 50.40 |
| Day's Volume | 1,018,358 |
| 52-Week Range | 30.02 - 58.72 |
Acadia (ACAD) delivered earnings and revenue surprises of 12.50% and -1.52%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced financial results for the fourth quarter and full year ended December 31, 2020. “Acadia delivered strong ...
On Wednesday, February 24, ACADIA Pharmaceuticals (NASDAQ:ACAD) will release its latest earnings report. Check out Benzinga's preview to understand the implications.
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the launch of MoreThanMemoryLoss.com, a new website with educational resources designed to help caregiver...
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following investor conferences: 10th Annual SVB Leerink Global Healthcare...
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2020 financial results on Wednesday, February 24, 2021, ...
After a nice close to 2020, Acadia's shares hit a slick spot in 2021.When they are waxing, as they so often do, Acadia's shares are good candidates for selling covered calls.
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Michael Yang, Executive Vice President and Chief Commercial Officer, will be leaving the organizatio...
ACADIA Pharmaceuticals Inc.'s (ACAD) CEO Stephen Davis at 39th Annual J.P. Morgan Healthcare Conference (Transcript)
DENVER--(BUSINESS WIRE)--Shuman, Glenn & Stecker Investigates Acadia Pharmaceuticals, Inc.
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021, a...
After an incredibly wild and wooly year for investors, many across Wall Street are cautiously optimistic for 2021.
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?
The health care sector as a whole has been a top performer this year, and there is every reason to believe that strong performance will carry through to 2021.
Let's see if Acadia Healthcare (ACHC) stock is a good choice for value-oriented investors right now from multiple angles.
ACADIA Pharmaceuticals Inc.'s (ACAD) Management Presents at 2020 Stifel Virtual Healthcare Conference (Transcript)
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17, 2020, at 3...
ACADIA's (ACAD) earnings fall shy of estimates in the third quarter while revenues beat the same. The company maintains its net sales guidance for Nuplazid.
ACADIA Pharmaceuticals Inc.'s (ACAD) CEO Steve Davis on Q3 2020 Results - Earnings Call Transcript
Acadia (ACAD) delivered earnings and revenue surprises of -42.11% and 1.52%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet me...
Let us take a look at some drug/biotech stocks that are poised to beat on third-quarter earnings.
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another...
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that scientific presentations highlighting new analyses of pimavanserin clinical study data in dementia-r...
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter financial results on Wednesday, November 4, 2020, after the close of th...
Our indicative theme of Out Of Favor Healthcare Stocks is down by about -10% year-to-date, versus the S&P 500 which is up by about 8% year-to-date. This theme includes healthcare and pharma co...
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Elizabeth (Betsy) Garofalo, M.D. to its Board of Directors. Dr. Garofalo is a biopharm...
ACADIA Pharmaceuticals, Inc. (ACAD) CEO Steve Davis Presents at Cantor Virtual Global Healthcare Conference (Transcript)
ACADIA Pharmaceuticals Inc. (ACAD) CEO Steve Davis Presents at Morgan Stanley 18th Annual Global Healthcare Conference (Transcript)
SAN DIEGO, Sept. 5, 2020 /PRNewswire/ -- Johnson Fistel, LLP is investigating potential claims on behalf of ACADIA Pharmaceuticals Inc.
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?
Spot the best cheap stocks to buy under $5 with the right catalyst at the right time, and it could lead to your next double-digit opportunity. The post 3 Cheap Stocks to Buy for Under $5 Now ...
SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming virtual investor conferences: Citi 15th Annual BioPhar...
SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Dr.
ACADIA (ACAD) purchases CerSci Therapeutics and in turn, secures the global rights to a suite of novel compounds for neurological disorders comprising non-opioid therapies for acute and chroni...
SAN DIEGO & FORT WORTH, Texas--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the acquisition of CerSci Therapeutics, a clinical-stage biotechnology company with w...
SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at The JMP Securities CNS Forum on Wednesday, August 19, 2020, at 11:00 a.m.
ACADIA (ACAD) beats on earnings and revenues for the second quarter. The company lifts the lower end of its net sales view for Nuplazid, driving the stock in pre-market trading.
ACADIA Pharmaceuticals, Inc. (ACAD) CEO Stephen Davis on Q2 2020 Results - Earnings Call Transcript
Acadia (ACAD) delivered earnings and revenue surprises of 38.64% and 4.22%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet me...
San Diego, California--(Newsfile Corp. - July 31, 2020) - If you would like to discuss your legal rights email leo@barrlaw.com or call (619) 780-3993.
SANTA MARIA, Calif. & SAN DIEGO--(BUSINESS WIRE)---- $ACAD--Stephens & Stephens LLP is investigating the officers and directors of ACADIA Pharmaceuticals Inc.
Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
WASHINGTON & ATLANTA & SAN DIEGO--(BUSINESS WIRE)--UsAgainstAlzheimer’s, the Lewy Body Dementia Association and ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the results of a qual...
ACADIA's (ACAD) second-quarter 2020 results are likely to reflect lower revenues from Nuplazid due to the adverse impacts of COVID-19.
About ACAD
ACADIA Pharmaceuticals, a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in Phase III clinical trials; and pimavanserin as an adjunctive treatment f... [Read more...]
| Industry Biotechnology | IPO Date May 27, 2004 |
| CEO Stephen Davis | Employees 580 |
| Stock Exchange NASDAQ | Ticker Symbol ACAD |
Financial Performance
In 2019, ACAD's revenue was $339.08 million, an increase of 51.50% compared to the previous year's $223.81 million. Losses were -$235.26 million, -4.05% less than in 2018.
Analyst Forecasts
According to 20 analysts, the average rating for ACAD stock is "Buy." The 12-month stock price forecast is 62.25, which is an increase of 27.85% from the latest price.